Summary: what the cases suggest

Most reports in this archive (65.9%) link the state to a medication or other substance. The two largest groups, antidepressants (124) and antipsychotics (117), together make up 48.6% of all cases. Many writers describe the state beginning or hardening after they stopped or changed a drug, not only while taking it. Across very different triggers, the descriptions sound strikingly alike. The most plausible shared explanation is a dampening of the brain's reward, motivation, and "salience" systems, the circuits that make thoughts feel urgent and experiences feel like they matter. Each trigger probably reaches that state by a different route. Among the 382 cases with a known outcome, 46 report full recovery, 66 partial recovery, and 270 no recovery at the time of writing.

Each case was sorted into one primary group based on what the writer blames. When a substance is named, the first substance mentioned wins. Otherwise the case falls to the first matching non-drug explanation. This is automated keyword sorting of free-text notes, so treat the boundaries as approximate. Some people took several drugs, and some drugs were given for an illness that may itself be involved.

473 of 496 cases (95.4%) state both halves of the cluster clearly: the blank mind and the numb emotions. The rest lean more on one side. That consistency is partly built in, because the archive only collects reports that match this pattern. Still, it is notable how often people with different triggers, languages, and communities reach for the same words: "empty head", "no inner monologue", "feel nothing", "zombie".

Other experiences come up often in the same reports. This is a simple keyword scan of the quote, cause, duration, and recovery notes, so the counts are lower bounds. A symptom that is not mentioned may still be present.

For the 327 substance-linked cases, the notes were scanned for signs of timing. The scan looked for words like "on-drug" or "while taking" versus "after stopping", "withdrawal", "cold turkey", or "lingering". Timing could be read for 221 of them. In 188 of those (85.1%), the state began after stopping or persisted past stopping. This is one of the most important patterns in the archive. A side effect that ends when a drug is stopped is well understood. A state that continues, or appears only after stopping, points to longer-lasting adaptation in the brain.

347 of 496 cases (70%) give a length of time in their duration note. The chart uses the longest span mentioned in each note. That is rough: some notes count time spent on the drug rather than time with symptoms. The median longest span mentioned is about 1 year. Many reports describe a state measured in months to years, not days.

Across the archive, 46 cases report recovery, 66 partial recovery, 270 no recovery at the time of writing, and 114 have no known outcome. Among the 382 with a known outcome, 29.3% report at least partial improvement and 12% report full recovery.

Read this carefully. People tend to post when they are struggling, and many never post an update. "Not recovered" usually means "not recovered yet, when they wrote". The recovery stories that do exist often credit time, slow and gradual change, and sometimes stopping or lowering the drug they blamed.

None of the following is proven for any individual case. These are the leading hypotheses discussed in research and patient communities, matched to the cause groups above.

The triggers differ, but the descriptions converge. That suggests a shared final pathway rather than one single cause. The leading candidate is reduced activity in the mesolimbic dopamine reward-and-salience system. This system tags thoughts, memories, and experiences as worth attending to and worth feeling something about. When it is dampened, thoughts may stop arising spontaneously and emotions may lose their charge at the same time. Serotonin changes can act on this system indirectly, antipsychotics block it directly, and inflammation, withdrawal, and chronic stress can all suppress it.

A second, overlapping idea involves the brain networks behind inner speech, imagination, and emotional processing. These include the default-mode network, which is active during mind-wandering and self-reflection, and regions such as the insula and amygdala that give feelings their felt sense. Reduced connectivity in these networks is one way to picture a "blank" inner world. It would also fit the overlap with depersonalisation.

These are hypotheses, not established explanations for this symptom cluster, and the archive cannot test them.

• AI interpretation. The groupings and explanations on this page were generated by an AI from the archive. They are not reviewed by a clinician and are not a scientific conclusion.
• Self-selected and self-reported. Cases are public posts that matched the search criteria. They are not a random sample, and they cannot show how common this is, or whether a given drug caused it.
• Where people post shapes the numbers. Groups that have active online communities (for example PSSD, antipsychotic, or long-COVID forums) will appear larger.
• Automated classification. Cause, timing, duration, and co-symptoms are read from free-text notes with keyword rules. Some cases will be sorted imperfectly, especially when several drugs or conditions are involved. Timing could be read for 221 of 327 substance-linked cases. A duration was given for 347 of 496 cases. 114 cases have no known outcome.
• Cases vs. people. Each case is one person where known. When the same person posted more than once, or crossposted, their posts are combined into a single case with every source listed, and its recovery status is the latest known one. 21 cases combine several posts or sources, so the 496 cases are built from 524 source posts. Posts are only combined when the same author is clear (cross-site matches need explicit evidence), so some repeat posters may still be counted more than once.
• Snapshots in time. Most reports capture one moment. Recovery status is as of the writer's last known post.

Please talk to a doctor or other qualified clinician. Bring specifics: what you took, when, at what dose, and when the change began. Do not stop or change a psychiatric medication suddenly on your own, because withdrawal effects can be serious. If you are in crisis, contact local emergency services or a crisis line.

• Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. British Journal of Psychiatry 2009;195(3):211–217. doi:10.1192/bjp.bp.108.051110
• Langley C, Armand S, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity. Neuropsychopharmacology 2023. doi:10.1038/s41386-022-01523-x
• European Medicines Agency, PRAC recommendations on signals adopted at the 13–16 May 2019 meeting: SSRIs/SNRIs – persistent sexual dysfunction after drug withdrawal. ema.europa.eu
• Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. International Journal of Risk & Safety in Medicine 2022;33(1):65–76. doi:10.3233/JRS-210023
• Neuroleptic-induced deficit syndrome (concept proposed by Lader and Lewander). Case series and discussion: Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis. PMC4745952